Analysts' Recent Ratings Updates for Acrivon Therapeutics (ACRV)
Analysts' Recent Ratings Updates for Acrivon Therapeutics (ACRV)
Several brokerages have updated their recommendations and price targets on shares of Acrivon Therapeutics (NASDAQ: ACRV) in the last few weeks:
几家经纪商已经更新了其对以下股票的建议和目标股价 Acrivon Therapeu （纳斯达克股票代码：ACRV）在过去的几周里：
- 12/12/2022 – Acrivon Therapeutics is now covered by analysts at Cowen Inc.. They set an "outperform" rating on the stock.
- 12/12/2022 – Acrivon Therapeutics is now covered by analysts at Cowen Inc. They set an "outperform" rating on the stock.
- 12/12/2022 – Acrivon Therapeutics is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $17.00 price target on the stock.
- 12/11/2022 – Acrivon Therapeutics is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $25.00 price target on the stock.
- 2022 年 12 月 12 日 — Acrivon Therapeutics 现在由 Cowen Inc. 的分析师负责他们对该股设定了 “跑赢大盘” 的评级。
- 2022年12月12日——Acrivon Therapeutics现在由Cowen Inc的分析师负责，他们对该股设定了 “跑赢大盘” 的评级。
- 2022 年 12 月 12 日 — Acrivon Therapeutics 现在由杰富瑞金融集团公司的分析师负责。他们为该股设定了 “买入” 评级和17.00美元的目标价格。
- 2022年12月11日——派珀·桑德勒的分析师现在负责Acrivon Therapeutics。他们对该股设定了 “增持” 评级和25.00美元的目标股价。
Acrivon Therapeutics Stock Up 0.1 %
Acrivon Therapeutics股票上涨0.1％
NASDAQ:ACRV opened at $11.51 on Wednesday. Acrivon Therapeutics, Inc. has a 52 week low of $10.90 and a 52 week high of $20.70.
纳斯达克股票代码：ACRV周三开盘价为11.51美元。Acrivon Therapeutics, Inc.创下52周低点10.90美元，创下52周高点20.70美元。
Insider Activity at Acrivon Therapeutics
Acrivon Therapeutics 的内部活动
In related news, major shareholder Ltd Chione purchased 400,000 shares of the firm's stock in a transaction on Thursday, November 17th. The stock was acquired at an average price of $12.50 per share, with a total value of $5,000,000.00. Following the completion of the acquisition, the insider now owns 3,856,597 shares in the company, valued at approximately $48,207,462.50. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director Ra Capital Management, L.P. purchased 3,389,500 shares of the firm's stock in a transaction on Thursday, November 17th. The stock was acquired at an average price of $12.50 per share, with a total value of $42,368,750.00. Following the completion of the acquisition, the director now owns 4,384,206 shares in the company, valued at approximately $54,802,575. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Ltd Chione acquired 400,000 shares of the business's stock in a transaction dated Thursday, November 17th. The stock was acquired at an average price of $12.50 per share, for a total transaction of $5,000,000.00. Following the purchase, the insider now directly owns 3,856,597 shares of the company's stock, valued at $48,207,462.50. The disclosure for this purchase can be found here.
在相关新闻中，主要股东Ltd Chione在11月17日星期四的一笔交易中购买了该公司40万股股票。该股以每股12.50美元的平均价格收购，总价值为5,000,000.00美元。收购完成后，该内部人士现在拥有该公司的3,856,597股股份，价值约为48,207,462.50美元。该交易是在向美国证券交易委员会提交的文件中披露的，该文件可通过以下方式获得 美国证券交易委员会网站。在相关新闻中，董事Ra Capital Management, L.P. 于11月17日星期四在一次交易中购买了该公司3,389,500股股票。该股以每股12.50美元的平均价格收购，总价值为42,368,750.00美元。收购完成后，该董事现在拥有该公司的4,384,206股股份，价值约为54,802,575美元。该交易是在向美国证券交易委员会提交的文件中披露的，该文件可通过以下方式获得 美国证券交易委员会网站。此外，主要股东Ltd Chione在11月17日星期四的一笔交易中收购了该公司的40万股股票。该股以每股12.50美元的平均价格收购，总交易额为5,000,000.00美元。收购后，知情人现在直接拥有该公司3,856,597股股票，价值48,207,462.50美元。可以找到此次收购的披露信息 这里。
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to specific medicine by utilizing its proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3).
Acrivon Therapeutics, Inc是一家临床阶段的生物制药公司，利用其基于蛋白质组学的患者应答者识别平台Acrivon Precision Precision Proteomics（AP3），致力于开发与预计肿瘤对特定药物敏感的患者相匹配的精准肿瘤药物。
Featured Stories
精选故事
- Get a free copy of the StockNews.com research report on Acrivon Therapeutics (ACRV)
- Is There a Prize in Store for Kellogg Shareholders?
- Will AMC's Troubles Affect Its Landlord, EPR Properties?
- General Mills Retreats To More Attractive Territory
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- 5 Down But Not Out Stocks To Watch For 2023
- 免费获取 StockNews.com 关于 Acrivon Therapeutics (ACRV) 的研究报告
- 凯洛格股东有奖金吗？
- AMC的麻烦会影响其房东EPR财产吗？
- 通用磨坊撤退到更具吸引力的领域
- 如果马斯克退出推特，特斯拉股价会上涨吗？
- 2023 年值得关注的 5 只下跌但尚未出局的股票
Receive News & Ratings for Acrivon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 Acrivon Therapeutics Inc 的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Acrivon Therapeutics Inc及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。